Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation

Inclusion criteria: * Male and female candidates (18 years of age and older) undergoing coronary bypass grafting surgery or valve repair or replacement - Aortic or Tricuspid or Pulmonary valves * Patients who are not previously on Ranolazine * Do not have a history of arrhythmia and are not on any antiarrhythmic therapy * Patients with QTc on a 12 lead EKG of less than or equal to 460 ms * Patients with estimated Glomerular Filtration Rate (GFR) greater than 30 mL/min/1.73 m2 on the initial lab work * Available at least 48 hours before surgery Exclusion criteria: * Patients who are not undergoing above surgeries * Patients undergoing surgery for mitral valve replacement/repair * Patient with cirrhosis * Pregnant patients * Patients with chronic atrial fibrillation * Patients who had prior adverse drug reactions or allergies to Ranolazine * Patients who are already taking Ranolazine prior to the study * Patient who are reported HIV Positive (as there are antiretroviral drug interactions) * Patients who are on drugs listed in Appendix A prior to the study